Fingerprint
Dive into the research topics of 'Second-generation tyrosine kinase inhibitors: The future of frontline CML therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Second-generation tyrosine kinase inhibitors: The future of frontline CML therapy
Hagop M. Kantarjian, Michele Baccarani, Elias Jabbour, Giuseppe Saglio, Jorge E. Cortes
Research output: Contribution to journal › Review article › peer-review
50
Scopus
citations